Article Sidebar
Views PDF: 63
THE EPIDEMIOLOGICAL CHARACTERISTICS OF NEUROFIBROMATOSIS TYPE 1 PATIENT TREATED AT VIET DUC UNIVERSITY HOSPITAL
Main Article Content
Abstract
Objectives: To describe some epidemiological characteristics of NF1 neurofibromatosis patients treated at Viet Duc University Hospital. Subjects of study: All patients diagnosed with neurofibromatosis with the results of pathology are neurofibromatosis type 1 (NF1) came for examination and treatment at the Department of Maxillofacial, Plastic and Aesthetic Surgery, Viet Duc University Hospital from 01/2008 to 12/2021. Objects and Methods: descriptive and prospective studies. Results: Total 128 patients, mean age of patients is 26.43 ± 15.79 years old; the lowest age is 1 years old, the highest is 73. Male/female ratio = 1.39/1. Tumor of head, face and neck (38.28%); lower expenditure (26.56%); body (17.97%); upper expenditure (14.84%); whole body (10.94%); genitals (1.56%). Conclusions: Neurofibromatosis is a disease with no specific treatment, early detection, regular progress monitoring, timely surgical treatment is the best way to help patients reduce the adverse effects caused by neurofibromatosis.
Article Details
Keywords
Neurofibromatosis, Neurofibromatosis type 1 (NF1) - Von Recklinghausen
References
2. Cnossen M, de Goede-Bolder A, Van den Broek K, et al.: A prospective 10 year follow up study of patients with neurofibromatosis type 1. Archives of disease in childhood. 1998, 78(5), 408-412.
3. Evans DG, Howard E, Giblin C, et al.: Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. American Journal of Medical Genetics Part A. 2010, 152A(2), 327-332.
4. Health NIo: National Institutes of Health consensus development conference statement: neurofibromatosis. Neurofibromatosis. 1988, 1, 172-178.
5. Huson SM, Compston DA, Harper PS: A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. Journal of medical genetics. Nov 1989, 26(11), 712-721.
6. Miettinen MM, Antonescu CR, Fletcher CDM, et al.: Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Human pathology. Sep 2017, 67, 1-10.
7. Rasmussen SA, Yang Q, Friedman JM: Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. American journal of human genetics. May 2001, 68(5), 1110-1118.
8. Weiss B, Bollag G, Shannon K: Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. American journal of medical genetics. Mar 26 1999, 89(1), 14-22.